Skip to main content
Full access
Editorials
Published Online: 1 August 2024

Neuroanatomical Subtyping of Phobias: Implications for Function and Development

Publication: American Journal of Psychiatry
Anxiety disorders are the most common of mental illnesses (1), yet their pathophysiology remains poorly understood. Despite over two decades of neuroimaging research, which has outlined some of the key brain circuitry underpinning anxiety-relevant processes (2, 3), we have yet to find robust brain-based biomarkers of anxiety. This has in part contributed to the cutbacks and discontinuation of drug discovery anxiety research seen in the private sector (4).
One of the methodological factors contributing to a lack of robust markers derives from issues of statistical power. Some have argued that establishing robust brain-behavior relationships demands thousands of participants (5). Anxiety research has not traditionally used designs of this magnitude. Smaller-scale studies are undoubtedly essential for scientific discovery (6), but our neuroscientific models of anxiety have faced minimal validation against highly powered samples. Studies that attempt this have not always replicated key findings, such as an association between resting-state functional connectivity of the amygdala and self-reported trait anxiety (7, 8), emphasizing the necessity of scrutinizing anxiety theory against larger data sets.
From a conceptual standpoint, a further hindrance to the identification of robust biomarkers may be from the very operationalization of anxiety as a unity construct, which has carved artificial boundaries with other forms of mental illness. The field has started to move toward a transdiagnostic approach which acknowledges that anxiety has shared mechanisms with other disorders, such as depression, as well as unique, disorder-specific features (9). On the other hand, while researchers have started to broaden the lens to encapsulate cross-disorder mechanisms, far less work has focused on idiosyncratic features underlying subtypes of anxiety disorders. Meta-analytic evidence supports the notion of common circuitry shared across anxiety disorders (as well as adaptive anxiety and fear [2, 3]), but we know far less about how, or indeed if, disorder subtypes differ. In sum, despite an increased uptake in transdiagnostic approaches, there is a clear need for exploring neuroimaging-based stratification of anxiety subtypes.
In this issue, Hilbert et al. (10) report on the largest study of its kind to investigate brain structure differences in phobias, focusing on two subtypes: animal phobia and blood-injury-injection phobia. Leveraging multisite data from over 4,400 participants (2,991 healthy volunteers and 1,452 volunteers with a phobia), the researchers’ preregistered mega-analysis tested for phobia-associated differences in brain structure (i.e., subcortical volume, cortical surface area, and cortical thickness) relative to healthy control subjects. They found an overall reduction in subcortical volumes, namely, the caudate, putamen, and hippocampus for individuals with a phobia (vs. healthy controls), except for the pallidum, which was generally larger in the phobia group. These effects appeared primarily driven by participants with animal phobias (N=739). Conversely, participants with a phobia demonstrated predominantly increased gray matter thickness and surface area across various cortical regions, such as the medial orbitofrontal cortex, frontal pole, and occipital regions. Orbitofrontal thickening was particularly pronounced among participants with blood-injury-injection phobia (N=182). Many of these effects survived a battery of robustness tests, were of a magnitude higher than those seen in studies of generalized and social anxiety disorders, and corroborate the authors’ prior findings in smaller samples (11). Combined with preregistered hypothesis testing and a relatively large sample size, Hilbert and colleagues’ findings give optimism to the idea that identifying robust brain-based measures of pathology is achievable in anxiety research.
Identifying biomarkers is, of course, only the start; to advance our theoretical understanding, we need to map markers onto underlying mechanisms (12). Indeed, in stark contrast with the commonly held view of the amygdala as the “fear center” (13), there were no differences in amygdala volume between the healthy and phobia samples. This does not preclude the functional involvement of the amygdala, nor morphology of amygdala subnuclei, in anxiety-relevant processes, but it begs the question of how and when these neuroanatomical differences in phobia impact brain activation. To this end, a meta-analysis of activation to emotion tasks among phobia patients, published in the Journal in 2021 (2), provides an opportunity to compare structural and functional differences region to region across the brain in phobia, as illustrated in Figure 1.
FIGURE 1. Association between brain structure and activation in individuals with a phobia and healthy volunteersa
aThe graphs show bivariate correlations between meta-analytic brain activation to emotion tasks (specific phobia vs. healthy volunteers, a subset of the full analyses that looked at all anxiety disorders [2]) and mega-analytic measures of subcortical volumes (eight regions), cortical surface area (34 regions), and cortical surface thickness (34 regions) for phobic versus healthy volunteers (adults only) (10).
The analysis summarized in the figure provides preliminary evidence for an overall negative relationship between function and structure, especially between cortical surface area and functional activation to emotion tasks in relation to phobias (r=−0.34, p=0.047). Regions for which individuals with a phobia tend to have a smaller surface area are associated with greater increases in blood-oxygen-level-dependent activation to emotion tasks. Exemplifying this is the anterior/mid-cingulate cortex, frequently reported as showing hyperactivation in participants with anxiety (14, 15), which appears to show reduced surface area. One interpretation is that a reduced surface area might necessitate greater metabolic and functional activity to achieve the required processing demands of emotional stimuli, which are often biased in patients with phobias (16). This relationship is of course tentative, given the broad comparisons of summary statistics between data sets (as opposed to subject-level metrics) and the cross-sectional nature of the correlations we present here. We also can’t rule out the possibility that this effect is driven by differences in how mega- and meta-analytic data points were adjusted for covariates otherwise associated with anxiety symptomatology and cortical morphology. Nonetheless, we must acknowledge there are likely inextricable structure-function relationships shaping cognition and behavior (17) that have, for the most part, been neglected in anxiety research.
It is unclear whether anxiety-relevant brain function changes precede, and potentially drive, structural changes in the brain or vice versa. A fruitful avenue for exploring structure-function relationships in anxiety may come through closer multimodal examination of developmental trajectories. Hilbert et al. report that an association between brain structure and phobia was observed only in adults. Yet, there is a plethora of evidence demonstrating differential brain activation among children and adolescents with anxiety disorders (18). Speculatively, such activation in the absence of structural differences suggests that function may be driving morphological differences during development. However, there is scant longitudinal evidence directly exploring this in pediatric anxiety, and it is nonetheless likely a bidirectional relationship. Understanding the developmental pathways that give rise to these causal influences between structure and function holds implications for neural malleability in response to treatment, underscoring the importance of age at which treatments for phobia start.
For future studies addressing structure-function hypotheses, we also emphasize strong consideration of the specificity of functional activation. We have previously demonstrated that naturalistic neuroimaging paradigms (i.e., suspenseful movies) can elicit differential—and even inverse—brain responses compared to traditional designs, such as using unpredictable shock and resting state (8, 1921). This negative correlation between surface area and phobia-dependent brain activity to emotion tasks may thus differ depending on the type of anxiogenic stimulus. Yet, there is a clear lack of naturalistic neuroimaging data collected from individuals with pathological anxiety. We therefore encourage future investigations into anxiety to consider these paradigms, especially when contextualizing associations between structure and function.
In an age when the outlook for neuroimaging-derived biomarkers can seem bleak, Hilbert and colleagues’ work provides robust evidence for neuroanatomical differences among and between individuals with a phobia. Their evidence points to generally decreased subcortical volumes (except in the pallidum) and increased cortical thickness and surface area in volunteers with a phobia (compared with healthy control subjects). Moreover, phobia subtypes differed in measures such as frontal pole and medial orbitofrontal cortex thickness. However, contrary to a plethora of functional evidence, there was no indication of individuals with a phobia having altered whole-amygdala volumes. When contrasted with functional imaging data, there is a general negative association between cortical surface area and activation (r=−0.34), opening an avenue for exploring structure-function associations in anxiety. Going forward, we suggest that developmental and naturalistic neuroimaging methods will be crucial for understanding the interplay of brain structure and function in the context of anxiety.

References

1.
Yang X, Fang Y, Chen H, et al: Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019. Epidemiol Psychiatr Sci 2021; 30:e36
2.
Chavanne AV, Robinson OJ: The overlapping neurobiology of induced and pathological anxiety: a meta-analysis of functional neural activation. Am J Psychiatry 2021; 178:156–164
3.
Shackman AJ, Fox AS: Two decades of anxiety neuroimaging research: new insights and a look to the future. Am J Psychiatry 2021; 178:106–109
4.
Hyman SE: Revolution stalled. Sci Transl Med 2012; 4:155cm11
5.
Marek S, Tervo-Clemmens B, Calabro FJ, et al: Reproducible brain-wide association studies require thousands of individuals. Nature 2022; 603:654–660
6.
Rosenberg MD, Finn ES: How to establish robust brain–behavior relationships without thousands of individuals. Nat Neurosci 2022; 25:835–837
7.
Boeke EA, Holmes AJ, Phelps EA: Toward robust anxiety biomarkers: a machine learning approach in a large-scale sample. Biol Psychiatry Cogn Neurosci Neuroimaging 2020; 5:799–807
8.
Kirk PA, Holmes AJ, Robinson OJ: Threat vigilance and intrinsic amygdala connectivity. Hum Brain Mapp 2022; 43:3283–3292
9.
Cuthbert BN, Insel TR: Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 2013; 11:126
10.
Hilbert K, Boeken OJ, Langhammer T, et al: Cortical and subcortical brain alterations in specific phobia and its animal and blood-injection-injury subtypes: a mega-analysis from the ENIGMA Anxiety Working Group. Am J Psychiatry 2024; 181:728–740
11.
Hilbert K, Evens R, Maslowski NI, et al: Neurostructural correlates of two subtypes of specific phobia: a voxel-based morphometry study. Psychiatry Res 2015; 231:168–175
12.
Pine DS, Leibenluft E: Biomarkers with a mechanistic focus. JAMA Psychiatry 2015; 72:633–634
13.
LeDoux JE: Thoughtful feelings. Curr Biol 2020; 30:R619–R623
14.
Robinson OJ, Charney DR, Overstreet C, et al: The adaptive threat bias in anxiety: amygdala–dorsomedial prefrontal cortex coupling and aversive amplification. Neuroimage 2012; 60:523–529
15.
Robinson OJ, Krimsky M, Lieberman L, et al: Towards a mechanistic understanding of pathological anxiety: the dorsal medial prefrontal-amygdala “aversive amplification” circuit in unmedicated generalized and social anxiety disorders. Lancet Psychiatry 2014; 1:294–302
16.
Waters AM, Bradley BP, Mogg K: Biased attention to threat in paediatric anxiety disorders (generalized anxiety disorder, social phobia, specific phobia, separation anxiety disorder) as a function of “distress” versus “fear” diagnostic categorization. Psychol Med 2014; 44:607–616
17.
Johansen-Berg H: Imaging the relationship between structure, function and behaviour in the human brain. Brain Struct Funct 2009; 213:499–500
18.
Zugman A, Winkler AM, Pine DS: Recent advances in understanding neural correlates of anxiety disorders in children and adolescents. Curr Opin Psychiatry 2021; 34:617–623
19.
Kirk PA, Robinson OJ, Skipper JI: Anxiety and amygdala connectivity during movie-watching. Neuropsychologia 2022; 169:108194
20.
Kirk PA, Holmes AJ, Robinson OJ: Anxiety shapes amygdala-prefrontal dynamics during movie watching. Biol Psychiatry Glob Open Sci 2023; 3:409–417
21.
Kirk PA, Robinson OJ: Preliminary evidence for altered brain-heart coherence during anxiogenic movies. Imaging Neurosci 2024; 2:1–15

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 693 - 695

History

Accepted: 7 June 2024
Published online: 1 August 2024
Published in print: August 01, 2024

Keywords

  1. Specific Phobia
  2. Neuroanatomy
  3. Neuroimaging

Authors

Affiliations

Peter A. Kirk, Ph.D. [email protected]
Emotion and Development Branch, NIMH, Bethesda, Md. (Kirk); Institute of Cognitive Neuroscience and Department of Clinical, Educational, and Health Psychology, University College London (Robinson).
Oliver J. Robinson, Ph.D.
Emotion and Development Branch, NIMH, Bethesda, Md. (Kirk); Institute of Cognitive Neuroscience and Department of Clinical, Educational, and Health Psychology, University College London (Robinson).

Notes

Send correspondence to Dr. Kirk ([email protected]).

Competing Interests

Dr. Robinson has served as a consultant for BlackThorn Therapeutics, IESO Digital Health, Peak, and Roche and has served on the council of the British Association of Psychopharmacology. Dr. Kirk reports no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share